Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Emphysema Pipeline Review, H2 2016, provides an overview of the Emphysema (Respiratory) pipeline landscape.
Emphysema is a type of COPD involving damage to the alveoli in the lungs. Symptoms include shortness of breath and cough with sputum. Risk factors include age, smoking, exposure to air pollutions, factory fumes, coal and silica dust. Treatment includes bronchodilators, antibiotics and steroids.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Emphysema Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Emphysema (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Emphysema (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Emphysema and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 1, 8 and 1 respectively for Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively for Emphysema.
Emphysema (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Emphysema (Respiratory).
- The pipeline guide reviews pipeline therapeutics for Emphysema (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Emphysema (Respiratory) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Emphysema (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Emphysema (Respiratory)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with p
